These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2935497)

  • 1. Chronic effect of ketanserin in mild to moderate essential hypertension.
    Woittiez AJ; Wenting GJ; van den Meiracker AH; Ritsema van Eck HJ; Man in't Veld AJ; Zantvoort FA; Schalekamp MA
    Hypertension; 1986 Feb; 8(2):167-73. PubMed ID: 2935497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects.
    Stokes GS; Mennie BA; Marwood JF
    Clin Pharmacol Ther; 1986 Jul; 40(1):56-63. PubMed ID: 2941206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trial of ketanserin in hypertension.
    McGourty JC; Silas JH; Cowen KJ
    Br J Clin Pharmacol; 1985 Jul; 20(1):37-40. PubMed ID: 3161531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
    Cameron HA; Ramsay LE
    Postgrad Med J; 1985 Jul; 61(717):583-6. PubMed ID: 3161013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
    Levinson PD; Zimlichman R; Goldstein DS; Keiser HR
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):384-9. PubMed ID: 2465437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin versus propranolol in the treatment of mild and moderate essential hypertension: corroboration with ambulatory blood pressure monitoring.
    Novo S; Alaimo G; Giordano U; Raineri A; Strano A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S104-6. PubMed ID: 2446055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ketanserin and metoprolol in the treatment of essential hypertension.
    Sheps SG; Schirger A; Zachariah PK; Fisher LD; Spiekerman RE; Araas FJ; Collins JB; Agerter DC
    Arch Intern Med; 1987 Feb; 147(2):291-6. PubMed ID: 3545116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ketanserin and pindolol in hypertension.
    Gordin A; Saraste K; Turanlahti M; Sundberg S
    J Hypertens Suppl; 1986 Apr; 4(1):S61-2. PubMed ID: 2939214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of ketanserin and metoprolol in essential hypertension.
    Seedat YK; Parag KB
    S Afr Med J; 1985 Oct; 68(8):555-8. PubMed ID: 2931840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
    Levinson PD; Zimlichman R; Goldstein DS; Brewer HB; Keiser HR
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):245S-248S. PubMed ID: 3415801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of ketanserin and metoprolol in essential hypertension.
    Kane JA; Tooley M; Sibbald B; Gould SE
    J Hypertens Suppl; 1986 Apr; 4(1):S63-5. PubMed ID: 2939215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S164-7. PubMed ID: 2412043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparative study of ketanserin with atenolol in essential hypertension.
    Antonicelli R; Andreoni A; Saccomanno G; Gambini C; Paciaroni E
    Drugs Exp Clin Res; 1989; 15(11-12):577-81. PubMed ID: 2700320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.